C4 Therapeutics (CCCC) Non-Current Debt (2020 - 2023)
C4 Therapeutics (CCCC) posted quarterly Non-Current Debt of $10.3 million for Q2 2023, little changed year-over-year from $10.4 million in Q2 2022, and down 12.04% quarter-over-quarter from $11.8 million in Q1 2023.
C4 Therapeutics (CCCC) Non-Current Debt (2020 - 2023) Analysis & Trends
C4 Therapeutics' Non-Current Debt history runs 4 years deep, the most recent figure standing at $10.3 million for Q2 2023.
- In Q2 2023, Non-Current Debt changed 0.36% year-over-year to $10.3 million; the TTM figure through Jun 2023 stood at $10.3 million (changed 0.36% YoY), while the FY2022 annual figure was $9.2 million, down 14.61% from the prior year.
- Non-Current Debt for Q2 2023 stood at $10.3 million, down from $11.8 million in the prior quarter.
- The five-year high for Non-Current Debt was $11.8 million in Q1 2023, with the low at $9.1 million in Q3 2022.
- The 4-year median for Non-Current Debt is $10.3 million (2021), against an average of $10.2 million.
- The sharpest annual moves came in 2022 and 2023: Non-Current Debt fell 14.61% in 2022, then grew 15.26% in 2023.
- C4 Therapeutics' Non-Current Debt stood at $10.1 million in 2020, then climbed by 7.12% to $10.8 million in 2021, then declined by 14.61% to $9.2 million in 2022, then increased by 12.4% to $10.3 million in 2023.
- Business Quant data shows CCCC's Non-Current Debt at $10.3 million in Q2 2023, $11.8 million in Q1 2023, and $9.2 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | C4 Therapeutics | 521.12 Mn | 267.46 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 10.34 Mn |
| Mar 31, 2023 | 11.75 Mn |
| Dec 31, 2022 | 9.20 Mn |
| Sep 30, 2022 | 9.05 Mn |
| Jun 30, 2022 | 10.37 Mn |
| Mar 31, 2022 | 10.19 Mn |
| Dec 31, 2021 | 10.77 Mn |
| Sep 30, 2021 | 10.59 Mn |
| Jun 30, 2021 | 10.41 Mn |
| Mar 31, 2021 | 10.23 Mn |
| Dec 31, 2020 | 10.05 Mn |
| Sep 30, 2020 | 9.88 Mn |